```html

Severe Acute Respiratory Syndrome (SARS)

Overview

Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused by the Severe Acute Respiratory Syndrome coronavirus (SARS‑CoV). The disease first emerged in the Guangdong province of China in November 2002 and spread to 26 countries, resulting in a global outbreak in 2003.

• Who it affects: SARS can affect anyone, but adults aged 30‑50 years and health‑care workers were disproportionately represented in the 2003 epidemic.
• Prevalence: According to the World Health Organization (WHO), there were 8,098 probable cases worldwide, of which 774 (≈9.6 %) died. After 2004, only sporadic, laboratory‑confirmed cases have been reported, making SARS a “rare but serious” disease today.
• Geographic distribution: The majority of cases occurred in mainland China (5,327), Hong Kong (1,755), Taiwan (346), Singapore (238), and Canada (251). The disease has not become endemic.

Because SARS is caused by a coronavirus closely related to the viruses that cause COVID‑19 and MERS, understanding its clinical picture helps clinicians recognize and manage novel coronavirus infections.

Symptoms

Symptoms typically appear 2–10 days after exposure (median 5 days). The clinical course can be mild, moderate, or severe. Below is a comprehensive list with brief descriptions.

Symptom	Typical Presentation
Fever	High-grade (≥38 °C/100.4 °F), often the first sign.
Dry cough	Persistent, non‑productive; may become productive later.
Shortness of breath (dyspnea)	Usually develops 5–7 days after fever; can progress to respiratory failure.
chills / rigors	Intermittent shaking episodes accompanying fever.
Myalgia	Muscle aches, especially in the back and thighs.
Headache	Often dull and constant.
Fatigue	Profound tiredness that limits daily activities.
Sore throat	Mild to moderate, may be mistaken for a common cold.
Chest pain	Often pleuritic in nature; may indicate pneumonia.
Gastro‑intestinal symptoms	Nausea, vomiting, or diarrhea in up to 25 % of patients.
Loss of appetite	Common early sign, contributes to weight loss.
Confusion or delirium	Seen in severe cases with hypoxia or sepsis.

Approximately 20 % of patients develop severe pneumonia requiring intensive‑care support, while a small minority become critically ill with multi‑organ failure.

Causes and Risk Factors

Cause

SARS is caused by infection with the novel coronavirus SARS‑CoV, a single‑stranded RNA virus belonging to the Betacoronavirus genus. The virus is thought to have originated in bats and then jumped to civet cats before infecting humans, a classic zoonotic spill‑over pattern.

Transmission

• Respiratory droplets: Coughing, sneezing, or talking can disperse infectious particles up to 1 meter.
• Close contact: Direct skin‑to‑skin contact or exposure to contaminated surfaces (fomites) can transmit the virus, especially in health‑care settings.
• Aerosol‑generating procedures: Intubation, bronchoscopy, or non‑invasive ventilation markedly increase risk for health‑care workers.

Risk Factors

• Living or working in close proximity to an infected person (family members, roommates, health‑care staff).
• Age ≥ 60 years – higher risk of severe disease and mortality.
• Underlying chronic illnesses: cardiovascular disease, diabetes, chronic lung disease, immunosuppression.
• Smoking – impairs mucociliary clearance and may increase viral entry.
• Pregnancy – physiological changes in immunity may predispose to severe infection.

Diagnosis

Timely diagnosis is essential to isolate cases and initiate supportive care. The diagnostic approach combines clinical suspicion with laboratory and imaging studies.

1. Clinical assessment

• History of exposure within the previous 14 days (travel to an outbreak area, contact with a confirmed case).
• Presence of fever and lower‑respiratory‑tract symptoms.

2. Laboratory tests

• Real‑time reverse transcription polymerase chain reaction (RT‑PCR): Detects SARS‑CoV RNA from nasopharyngeal, throat, or lower‑respiratory specimens. It is the gold standard (sensitivity 70‑80 % early, >95 % after day 5).
• Serology: IgM and IgG antibodies become detectable 10–14 days after symptom onset; useful for retrospective confirmation.
• Complete blood count: Often shows lymphopenia (<1.0 × 10⁹ cells/L) and thrombocytopenia.
• Elevated inflammatory markers (CRP, ferritin, LDH) may correlate with severity.

3. Imaging

• Chest X‑ray: May reveal bilateral infiltrates or patchy opacities.
• High‑resolution computed tomography (CT): More sensitive; typical findings include ground‑glass opacities, peripheral consolidation, and “crazy‑paving” patterns.

4. Differential diagnosis

Influenza, COVID‑19, MERS, bacterial pneumonia, and other viral pneumonias must be ruled out, especially during flu season.

Treatment Options

To date, no antiviral drug has been proven definitively effective against SARS‑CoV. Management focuses on supportive care and infection control.

1. Supportive care

• Oxygen therapy: Nasal cannula, face mask, or high‑flow nasal oxygen to maintain SpO₂ ≥ 94 %.
• Ventilatory support: Non‑invasive ventilation (NIV) for moderate hypoxemia; early intubation and mechanical ventilation for progressive respiratory failure.
• Fluid management: Conservative strategy to avoid pulmonary edema.
• Nutritional support: High‑protein diet or enteral feeding when oral intake is insufficient.

2. Pharmacologic interventions (investigational)

• Ribavirin: Used during the 2003 outbreak but did not show clear benefit and caused hemolytic anemia.
• Lopinavir/ritonavir: HIV protease inhibitors studied in limited case series; data are inconclusive.
• Interferon‑α: In vitro activity against coronaviruses; clinical evidence lacking.
• Corticosteroids: High‑dose steroids were employed to dampen inflammatory lung injury, but later analyses linked them to delayed viral clearance and higher complication rates. Current guidelines recommend use only in clinical trial settings.

All pharmacologic options should be considered within a clinical trial or compassionate‑use framework and weighed against potential adverse effects.

3. Adjunctive therapies

• Antibiotics only if bacterial co‑infection is suspected.
• Thromboprophylaxis (low‑molecular‑weight heparin) for immobilized patients, given the high incidence of venous thromboembolism in severe viral pneumonia.
• Empiric antifungal therapy for prolonged ICU stays or immunosuppression.

4. Post‑acute care

Patients recovering from severe SARS often experience reduced lung capacity, muscle deconditioning, and psychological sequelae (e.g., PTSD). Structured pulmonary rehabilitation and mental‑health support improve long‑term outcomes.

Living with Severe Acute Respiratory Syndrome (SARS)

Although new cases are rare, people who have recovered from SARS may still have lingering health concerns. Below are practical tips for daily management.

• Monitor respiratory status: Keep a symptom diary. Seek care if cough worsens or new breathlessness occurs.
• Pulmonary rehabilitation: Engage in graded aerobic exercise (e.g., walking 10‑15 minutes, 3‑5 times weekly) under physiotherapist guidance.
• Vaccinations: Stay up‑to‑date with influenza and COVID‑19 vaccines to reduce the risk of secondary infections.
• Nutrition: Prioritize a balanced diet rich in protein, vitamins A, C, D, and zinc to support immune health.
• Stress management: Mind‑body techniques (deep breathing, meditation) can alleviate anxiety related to the prior illness.
• Regular follow‑up: Schedule periodic chest imaging and pulmonary function tests (PFTs) as recommended by your physician.
• Workplace considerations: If you work in health care, adhere strictly to infection‑control policies and report any respiratory symptoms promptly.

Prevention

Because SARS spreads primarily through close contact, prevention mirrors strategies used for other respiratory viruses.

• Hand hygiene: Wash hands with soap for ≥20 seconds or use an alcohol‑based sanitizer (≥60 % ethanol).
• Respiratory etiquette: Cover coughs/sneezes with a tissue or elbow; dispose of tissues safely.
• Mask use: In high‑risk settings (health‑care facilities, crowded indoor areas), wear a properly fitted surgical mask or N95 respirator.
• Physical distancing: Maintain at least 1 meter distance from individuals who are ill.
• Environmental cleaning: Regularly disinfect high‑touch surfaces (doorknobs, keyboards) with EPA‑approved agents.
• Travel awareness: Follow travel advisories from the CDC and WHO; avoid regions experiencing active coronavirus outbreaks.
• Vaccination research: While no specific SARS vaccine exists, ongoing studies of pan‑coronavirus vaccines may provide future protection.

Complications

If SARS progresses untreated—or even despite optimal care—several serious complications can arise.

• Acute respiratory distress syndrome (ARDS): Diffuse alveolar damage leading to refractory hypoxemia; may require extracorporeal membrane oxygenation (ECMO).
• Secondary bacterial or fungal pneumonia: Superinfection can worsen respiratory failure.
• Septic shock: Systemic inflammatory response causing multi‑organ dysfunction.
• Cardiac injury: Myocarditis, arrhythmias, or heart failure observed in 15‑20 % of severe cases.
• Renal failure: Acute kidney injury may develop, requiring dialysis.
• Neurologic sequelae: Encephalopathy, peripheral neuropathy, or cerebrovascular events.
• Psychiatric disorders: Anxiety, depression, and post‑traumatic stress disorder (PTSD) are common among survivors.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Severe acute respiratory syndrome (SARS).” Accessed June 2026.
2. World Health Organization. “Severe Acute Respiratory Syndrome.” WHO Fact Sheet, 2024. Link
3. Centers for Disease Control and Prevention. “SARS – Clinical Care Guidelines.” 2023. Link
4. National Institutes of Health. “Coronavirus (SARS) Treatment.” NIH Clinical Guidelines, 2022. Link
5. Cleveland Clinic. “SARS (Severe Acute Respiratory Syndrome).” 2023. Link
6. Peiris, J.S.M. et al. “Clinical progression and viral load in SARS patients.” The Lancet, 2003; 361:1767‑1772.
7. Lee, N. et al. “Outcomes of severe and critical SARS.” New England Journal of Medicine, 2004; 350:251–259.

```